BCV
BHVN

Banque Cantonale Vaudoise’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Banque Cantonale Vaudoise’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-338
Closed -$51K – 1268
2022
Q3 		$51K Buy
338
+44
+15% +$6.52K ﹤0.01% 987
2022
Q2 		$43K Sell
294
-143
-33% -$18.3K ﹤0.01% 1035
2022
Q1 		$52K Hold
437
– – ﹤0.01% 1041
2021
Q4 		$60K Buy
+437
New +$55.6K ﹤0.01% 1042

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Banque Cantonale Vaudoise's BHVN Position: Q4 2022 in Review

Banque Cantonale Vaudoise sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 338 shares — an estimated $51K sold.

Banque Cantonale Vaudoise first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $60K in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Banque Cantonale Vaudoise reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 338 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $51K.
  • Banque Cantonale Vaudoise first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • Banque Cantonale Vaudoise's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $60K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q4 2022, filed 10 Feb 2023.